Bayer Animal Health sees positive sales in Q2 2014

The Bayer Group was again successful in the second quarter of 2014. Sales of the Bayer Group rose by 0.9% in the second quarter to EUR 10,458 million (Q2 2013: EUR 10,360). Adjusted for currency and portfolio effects, sales advanced by 6,3%. EBIT rose by 14.5% to EUR 1.473 million (Q2 2013: EUR 1.287 million). 

Gross cash flow in the second quarter of 2014 advanced by 1.5% to EUR 1,705 million (Q2 2013: EUR 1,680 million) due to the improvement in EBITDA, while cash flow moved ahead by 4.2% to EUR 1,601 million (Q2 2013: EUR 1,536 million). Net financial debt increased from EUR 9.1 billion on March 31, 2014 to EUR 9.9 billion on June 30, 2014. 

READ MORE: Stockholders Newsletter Second Quarter 2014

Sales of HealthCare rose in the second quarter by 0.9% to EUR 4,485 million (Q2 2013: EUR 4,800 million). The Animal Health business developed positively with 5% growth to EUR 362 million (Q2 2013: EUR 358 million). The Seresto™ flea and tick collar contributed to this increase, partly on account of volume gains in the United STates. Sales of the Advantage™ line of flea, tick and worm control products showed a slight decrease. 

READ MORE: Bayer continues positive business development